Skip Navigation LinksHome > June 2014 - Volume 24 - Issue 5 > Survival After Curative Pelvic Exenteration for Primary or R...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0b013e3182a80aec
Cervical Cancer

Survival After Curative Pelvic Exenteration for Primary or Recurrent Cervical Cancer: A Retrospective Multicentric Study of 167 Patients

Chiantera, Vito MD; Rossi, Martina MD*†; De Iaco, Pierandrea MD; Koehler, Christardt PhD*; Marnitz, Simone PhD; Ferrandina, Gabriella MD§; Legge, Francesco MD; Parazzini, Fabio MD; Scambia, Giovanni PhD§; Schneider, Achim PhD*; Vercellino, Giuseppe Filiberto MD*

Collapse Box

Abstract

Objective

Evaluate the survival of patients who underwent pelvic exenteration (PE) with curative intent for primary persistent or recurrent cervical cancer.

Methods

We retrospectively investigated 167 consecutive patients, referred to the gynecological oncology units of 4 centers in Germany or Italy, who underwent PE. Data regarding surgery, histology, and oncologic outcomes were collected and statistically evaluated. Survival was determined from the day of exenteration until last follow-up or death.

Results

The median age was 51 years. Twenty-seven patients (16.2%) underwent PE owing to advanced primary tumors (group A), 34 patients (20.4%) underwent PE owing to persistent cancer after chemotherapy or chemoradiation (group B), and 106 patients (63.4%) underwent PE owing to recurrence (group C). The prevalent histologic type was squamous cell cancer. A complete tumor resection (R0), was achieved in 121 patients (72.5%). Forty-nine patients (29.3%) had pelvic lymph node metastases and 44 patients (26.3%) had pelvic sidewall involvement. Overall survival at the end of the study was 40.7%. The cumulative 5-year overall survival for the entire cohort was 38%. Resection margins, pelvic lymph node state, and sidewall involvement were independent prognostic factors in multivariate analysis.

Conclusion

Pelvic exenteration is a valid therapeutic option for patients with locally advanced primary persistent or recurrent cervical cancer, with a long-term survival in 40% of the patients.

Copyright © 2014 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.